GLP-1 Weight LossResults
What the clinical research actually shows about weight loss on GLP-1 medications. This page presents published data from peer-reviewed clinical trials — not anecdotes or personal outcomes. Individual results vary significantly.
About This Data
The weight loss data on this page comes from published, peer-reviewed clinical trials — primarily the STEP program (semaglutide), SURMOUNT program (tirzepatide), and SCALE program (liraglutide). These trials were conducted with specific patient populations and included lifestyle interventions (dietary counseling and exercise recommendations) alongside medication.
Individual results may differ substantially from these averages. Factors such as starting weight, diet quality, physical activity, medication adherence, and individual biology all influence outcomes. This page presents data for educational purposes and should not be used to set expectations for your own treatment. For a broader overview of these medications, see our What Are GLP-1 Medications? guide.
Results byMedication
Detailed clinical trial data for each major GLP-1 medication studied for weight loss.
Semaglutide (Wegovy)
The STEP (Semaglutide Treatment Effect in People with obesity) program is a series of clinical trials evaluating semaglutide 2.4mg for chronic weight management.
STEP 1 (Primary Weight Loss Trial)
- Participants: 1,961 adults with BMI 30+ (or 27+ with weight-related conditions)
- Duration: 68 weeks
- Average weight loss: 14.9% of body weight (vs. 2.4% with placebo)
- Notable: 86.4% of participants lost at least 5% of body weight
- Source: Wilding et al., New England Journal of Medicine (2021)
STEP 2 (Type 2 Diabetes Population)
- Participants: 1,210 adults with type 2 diabetes and BMI 27+
- Average weight loss: 9.6% of body weight (vs. 3.4% placebo)
- Note: Weight loss is typically lower in populations with type 2 diabetes
Tirzepatide (Zepbound)
The SURMOUNT program evaluated tirzepatide (a dual GIP/GLP-1 receptor agonist) for chronic weight management across multiple dose levels.
SURMOUNT-1 (Primary Weight Loss Trial)
- Participants: 2,539 adults with BMI 30+ (or 27+ with weight-related conditions)
- Duration: 72 weeks
- Average weight loss (15mg dose): 20.9% of body weight (vs. 3.1% placebo)
- Average weight loss (10mg dose): 19.5% of body weight
- Average weight loss (5mg dose): 15.0% of body weight
- Source: Jastreboff et al., New England Journal of Medicine (2022)
SURMOUNT-2 (Type 2 Diabetes Population)
- Participants: 938 adults with type 2 diabetes and BMI 27+
- Average weight loss (15mg): 14.7% of body weight
- Note: Weight loss is typically lower in populations with type 2 diabetes
Liraglutide (Saxenda)
The SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence) program studied liraglutide 3.0mg for chronic weight management. Liraglutide was one of the earlier GLP-1 receptor agonists approved for weight loss.
SCALE Obesity and Prediabetes Trial
- Participants: 3,731 adults with BMI 30+ (or 27+ with weight-related conditions)
- Duration: 56 weeks
- Average weight loss: 8.0% of body weight (vs. 2.6% placebo)
- Notable: 63.2% of participants lost at least 5% of body weight
- Administration: Daily injection (vs. weekly for semaglutide and tirzepatide)
- Source: Pi-Sunyer et al., New England Journal of Medicine (2015)
Weight LossTimeline
Based on aggregate clinical trial data, here is what the research shows about the typical pace of weight loss on GLP-1 medications. Individual timelines vary significantly.
Initial Response
The most rapid phase of weight loss in clinical trials. Dosage is typically being titrated upward during this period. Participants begin experiencing reduced appetite and initial weight changes.
Continued Loss
Weight loss continues at a steady pace for most participants. Many reach their target dose during this phase. Clinical trials show consistent downward trends in body weight through month 6.
Approaching Plateau
The rate of weight loss begins to slow for most participants. The body adapts to the lower caloric intake and reduced weight. Most clinical trials show the majority of weight loss occurring by this point.
Maintenance Phase
Weight typically stabilizes in what researchers call a "weight plateau." Clinical trials show weight maintenance (rather than continued loss) for most participants who continue medication.
Important: Individual timelines vary significantly. Some people may experience faster or slower weight loss than what clinical trials show on average. Factors including starting weight, diet, exercise, medication adherence, and individual metabolism all influence the timeline. Do not compare your progress to averages — discuss your individual trajectory with your healthcare provider.
Factors That InfluenceYour Results
Clinical trials and published research have identified several factors that influence weight loss outcomes on GLP-1 medications. Understanding these can help you have more productive conversations with your healthcare provider.
Starting Weight & BMI
Clinical trials suggest that individuals with higher starting BMI tend to lose a greater absolute amount of weight, though the percentage of body weight lost may vary. The body's metabolic response to medication is influenced by baseline weight and body composition.
Diet & Nutrition Quality
All major GLP-1 clinical trials included dietary counseling as part of the intervention. Nutrition quality — particularly adequate protein intake — influences both the amount and composition of weight lost. Research shows that adequate protein intake helps preserve lean muscle mass during weight loss.
Physical Activity
Exercise has been shown to enhance weight loss outcomes on GLP-1 medications. A study published in Nature Medicine found that combining structured exercise with GLP-1 medication resulted in approximately 24.5% total body weight loss — compared to 18.2% with medication alone.
Research finding: Exercise combined with GLP-1 medication resulted in approximately 21 additional pounds of weight loss compared to medication alone, while also preserving significantly more lean muscle mass.
Source: Nature Medicine (2024)
Medication Adherence
Consistent use of GLP-1 medications as prescribed is associated with better outcomes. Research shows that approximately 50% of patients discontinue GLP-1 medication within 12 months, and those who maintain consistent adherence tend to achieve and sustain greater weight loss.
Additional factors that may influence results include genetics, sleep quality, stress levels, metabolic health, insulin sensitivity, and concurrent medications. Discuss all of these factors with your healthcare provider for personalized guidance.
Track Your Progresswith Dose AI
While clinical trials provide population-level averages, your journey is individual. Dose AI helps you track the factors that research shows matter most — weight trends, nutrition, medication adherence, and symptoms. Dose AI is a tracking tool, not a medical device.
Weight Trend Tracking
Log daily or weekly weigh-ins and see your weight trend over time. Visual charts help you identify patterns and share progress with your healthcare provider.
Nutrition Monitoring
Track protein, calories, and macronutrients — the factors research shows influence weight loss composition and muscle preservation on GLP-1 medications.
Medication Adherence
Track injection dates and set reminders to maintain consistent medication use — a key factor in achieving and sustaining weight loss results.
Side Effect Logging
Record symptoms and side effects over time. Understanding patterns can help your healthcare provider optimize your treatment plan.
AI Food Scanner
Snap a photo of your meal and get instant nutrition data. Makes it easy to track protein and calories — even when appetite is reduced on GLP-1 medications.
Progress Sharing
Generate progress reports you can share with your doctor, including weight trends, nutrition data, and medication history — giving them a complete picture.
Key Numbers from the Research
Published clinical trial and research data
average weight loss on semaglutide
STEP 1 Trial, NEJM 2021
average weight loss on tirzepatide (15mg)
SURMOUNT-1, NEJM 2022
additional loss with exercise + GLP-1
Nature Medicine 2024
regained within 1 year of stopping
STEP 1 Extension
Medical Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before making any decisions about your health or medications.
Weight LossQuestions
Common questions about GLP-1 weight loss results, answered with published research data.
Have More Questions?How much weight can you lose on GLP-1 medications?
Clinical trials show average weight loss of 15-21% of body weight depending on the medication. The STEP 1 trial showed an average of 14.9% weight loss with semaglutide (Wegovy), while SURMOUNT-1 showed 20.9% with tirzepatide (Zepbound) at the highest dose. Individual results vary significantly based on factors including starting weight, diet, exercise, and medication adherence.
How quickly do you lose weight on Ozempic?
STEP clinical trials showed that most weight loss with semaglutide occurs in the first 6 months, with continued but slower weight loss through months 12 to 16. The rate of loss is typically most rapid during months 1-3 as dosage is being titrated upward. Individual timelines vary, and the rate depends on factors including diet, exercise, and how the body responds to the medication.
Do you gain weight back after stopping GLP-1 medications?
Research shows that participants regained approximately two-thirds of their lost weight within one year of stopping semaglutide in the STEP 1 extension trial. A separate study found an average regain of 5.15kg within 12 weeks of discontinuation. Maintaining lifestyle changes — including diet, exercise, and nutrition tracking — may help mitigate regain, though more research is needed. The decision to continue or stop medication should always be made with your healthcare provider.
Does exercise improve GLP-1 weight loss results?
Yes. Research published in Nature Medicine found that combining structured exercise with GLP-1 medication resulted in approximately 24.5% total body weight loss, compared to 18.2% with medication alone — a difference of roughly 21 additional pounds. Exercise also helped preserve lean muscle mass, which is important for long-term metabolic health and preventing weight regain.
Why do GLP-1 results vary between people?
GLP-1 weight loss results vary due to multiple factors including genetics, starting weight and BMI, dietary quality and caloric intake, physical activity level, medication adherence and consistency, metabolic health and insulin sensitivity, and sleep quality. Clinical trials represent averages across diverse populations, and individual outcomes can be significantly above or below the average.
Can Dose AI predict my weight loss?
No. Dose AI is a tracking tool that helps you monitor your progress and stay consistent with nutrition, medication, and healthy habits. It does not predict individual weight loss outcomes. The app helps you log weight trends over time, track nutrition and protein intake, monitor medication adherence, and share progress data with your healthcare provider — but it cannot predict how your body will respond to treatment.
Track Your GLP-1 Resultswith Dose AI
Clinical trials show averages. Your journey is unique. Dose AI helps you track the factors that research shows matter most — weight, nutrition, medication, and symptoms.
Free download · iOS · Premium features available
Dose AI is a tracking and information tool, not a medical device. It does not predict weight loss outcomes. Always consult your healthcare provider for medical advice about your GLP-1 medication.